3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Lung Neoplasms
3
Colorectal Neoplasms
3
Lymphoma
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Quality of Life
1
Pseudomyxoma Peritonei
1
Prostatic Neoplasms
1
Paranasal Sinus Neoplasms
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Mixed Dementias
1
Mesothelioma, Malignant
1
Meningeal Carcinomatosis
1
Maxillary Sinus Neoplasms
1
Lymphoma, Follicular
1
Lewy Body Disease
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Interventions
Cisplatin
30
Pemetrexed
21
Gemcitabine
11
Radiotherapy
6
Nivolumab
6
Drug Therapy
6
Cyclophosphamide
6
Carboplatin
6
durvalumab
4
Vinorelbine
4
Chemotherapy, Adjuvant
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
sodium thiosulfate
3
sargramostim
3
Ipilimumab
3
Doxorubicin
3
raltitrexed
2
pembrolizumab
2
cediranib
2
SS1(dsFv)PE38
2
Radiotherapy, Intensity-Modulated
2
Psychiatric Rehabilitation
2
Photochemotherapy
2
Neoadjuvant Therapy
2
Methotrexate
2
Interferon-alpha
2
Imatinib Mesylate
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Gefitinib
2
Everolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Mesothelioma, Malignant
×
Referral and Consultation
×
Clear all
NCT01126346
2018-07-03
HOPE
Wake Forest University Health Sciences
Phase NA
Completed
10 enrolled